460 related articles for article (PubMed ID: 20159823)
1. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.
Reid AH; Attard G; Danila DC; Oommen NB; Olmos D; Fong PC; Molife LR; Hunt J; Messiou C; Parker C; Dearnaley D; Swennenhuis JF; Terstappen LW; Lee G; Kheoh T; Molina A; Ryan CJ; Small E; Scher HI; de Bono JS
J Clin Oncol; 2010 Mar; 28(9):1489-95. PubMed ID: 20159823
[TBL] [Abstract][Full Text] [Related]
2. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
Attard G; Reid AH; A'Hern R; Parker C; Oommen NB; Folkerd E; Messiou C; Molife LR; Maier G; Thompson E; Olmos D; Sinha R; Lee G; Dowsett M; Kaye SB; Dearnaley D; Kheoh T; Molina A; de Bono JS
J Clin Oncol; 2009 Aug; 27(23):3742-8. PubMed ID: 19470933
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
Ryan CJ; Smith MR; Fong L; Rosenberg JE; Kantoff P; Raynaud F; Martins V; Lee G; Kheoh T; Kim J; Molina A; Small EJ
J Clin Oncol; 2010 Mar; 28(9):1481-8. PubMed ID: 20159824
[TBL] [Abstract][Full Text] [Related]
4. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.
Danila DC; Morris MJ; de Bono JS; Ryan CJ; Denmeade SR; Smith MR; Taplin ME; Bubley GJ; Kheoh T; Haqq C; Molina A; Anand A; Koscuiszka M; Larson SM; Schwartz LH; Fleisher M; Scher HI
J Clin Oncol; 2010 Mar; 28(9):1496-501. PubMed ID: 20159814
[TBL] [Abstract][Full Text] [Related]
5. Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer.
Omlin A; Pezaro CJ; Zaidi S; Lorente D; Mukherji D; Bianchini D; Ferraldeschi R; Sandhu S; Dearnaley D; Parker C; Van As N; de Bono JS; Attard G
Br J Cancer; 2013 Sep; 109(5):1079-84. PubMed ID: 23928659
[TBL] [Abstract][Full Text] [Related]
6. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?
Mezynski J; Pezaro C; Bianchini D; Zivi A; Sandhu S; Thompson E; Hunt J; Sheridan E; Baikady B; Sarvadikar A; Maier G; Reid AHM; Mulick Cassidy A; Olmos D; Attard G; de Bono J
Ann Oncol; 2012 Nov; 23(11):2943-2947. PubMed ID: 22771826
[TBL] [Abstract][Full Text] [Related]
7. Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer.
Salem M; Garcia JA
Curr Oncol Rep; 2011 Apr; 13(2):92-6. PubMed ID: 21243537
[TBL] [Abstract][Full Text] [Related]
8. Abiraterone acetate: a novel drug for castration-resistant prostate carcinoma.
Nandha R
J Postgrad Med; 2012; 58(3):203-6. PubMed ID: 23023354
[TBL] [Abstract][Full Text] [Related]
9. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).
Loriot Y; Bianchini D; Ileana E; Sandhu S; Patrikidou A; Pezaro C; Albiges L; Attard G; Fizazi K; De Bono JS; Massard C
Ann Oncol; 2013 Jul; 24(7):1807-1812. PubMed ID: 23576708
[TBL] [Abstract][Full Text] [Related]
10. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone.
Schrader AJ; Boegemann M; Ohlmann CH; Schnoeller TJ; Krabbe LM; Hajili T; Jentzmik F; Stoeckle M; Schrader M; Herrmann E; Cronauer MV
Eur Urol; 2014 Jan; 65(1):30-6. PubMed ID: 23849416
[TBL] [Abstract][Full Text] [Related]
11. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.
Bianchini D; Lorente D; Rodriguez-Vida A; Omlin A; Pezaro C; Ferraldeschi R; Zivi A; Attard G; Chowdhury S; de Bono JS
Eur J Cancer; 2014 Jan; 50(1):78-84. PubMed ID: 24074764
[TBL] [Abstract][Full Text] [Related]
12. [Abiraterone acetate (AA): current guidelines of prescription of abiraterone].
Boissier E; Loriot Y; Vignot S; Massard C
Bull Cancer; 2014 Apr; 101(4):388-93. PubMed ID: 24793632
[TBL] [Abstract][Full Text] [Related]
13. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.
Azad AA; Leibowitz-Amit R; Eigl BJ; Lester R; Wells JC; Murray RN; Kollmannsberger C; Heng DY; Joshua AM; Chi KN
Prostate; 2014 Nov; 74(15):1544-50. PubMed ID: 25175831
[TBL] [Abstract][Full Text] [Related]
14. Abiraterone and increased survival in metastatic prostate cancer.
de Bono JS; Logothetis CJ; Molina A; Fizazi K; North S; Chu L; Chi KN; Jones RJ; Goodman OB; Saad F; Staffurth JN; Mainwaring P; Harland S; Flaig TW; Hutson TE; Cheng T; Patterson H; Hainsworth JD; Ryan CJ; Sternberg CN; Ellard SL; Fléchon A; Saleh M; Scholz M; Efstathiou E; Zivi A; Bianchini D; Loriot Y; Chieffo N; Kheoh T; Haqq CM; Scher HI;
N Engl J Med; 2011 May; 364(21):1995-2005. PubMed ID: 21612468
[TBL] [Abstract][Full Text] [Related]
15. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide.
Noonan KL; North S; Bitting RL; Armstrong AJ; Ellard SL; Chi KN
Ann Oncol; 2013 Jul; 24(7):1802-1807. PubMed ID: 23585511
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
Massard C; Mateo J; Loriot Y; Pezaro C; Albiges L; Mehra N; Varga A; Bianchini D; Ryan CJ; Petrylak DP; Attard G; Shen L; Fizazi K; de Bono J
Ann Oncol; 2017 Jan; 28(1):90-95. PubMed ID: 28039155
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
Attard G; Reid AH; Yap TA; Raynaud F; Dowsett M; Settatree S; Barrett M; Parker C; Martins V; Folkerd E; Clark J; Cooper CS; Kaye SB; Dearnaley D; Lee G; de Bono JS
J Clin Oncol; 2008 Oct; 26(28):4563-71. PubMed ID: 18645193
[TBL] [Abstract][Full Text] [Related]
18. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
Ueda Y; Matsubara N; Takizawa I; Nishiyama T; Tabata K; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H
Jpn J Clin Oncol; 2015 Aug; 45(8):774-9. PubMed ID: 25981621
[TBL] [Abstract][Full Text] [Related]
19. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate.
Danila DC; Anand A; Sung CC; Heller G; Leversha MA; Cao L; Lilja H; Molina A; Sawyers CL; Fleisher M; Scher HI
Eur Urol; 2011 Nov; 60(5):897-904. PubMed ID: 21802835
[TBL] [Abstract][Full Text] [Related]
20. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.
Stein MN; Patel N; Bershadskiy A; Sokoloff A; Singer EA
Asian J Androl; 2014; 16(3):387-400. PubMed ID: 24759590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
